ABILD
ABILD partnership aims at enhancing health innovation projects to comprehend care gaps in diagnosis, treatment, and access for Albertans with progressive fibrosing ILD.
Search
Pommeraie collaborative COPD strategy
La Pommeraie's Collaborative COPD Strategy, with Boehringer Ingelheim Canada's Patient Access division, focuses on enhancing COPD patients' health and reducing hospitalizations.
Stefanie Bock Kreilinger
Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
ABIC Indigenous Populations
Improving primary care in Alberta’s Indigenous Populations. Read more about ABIC, an example of how delivering innovative solutions can improve health equity.
Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner
Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner
Alberta’s Dr. Calvin Booker named bovine veterinarian of the year by the Western Canadian Association of Bovine Practitioners
Alberta’s Dr. Calvin Booker named bovine veterinarian of the year by the Western Canadian Association of Bovine Practitioners
Dr. Todd Duffield named as the 2018 Metacam® 20* Bovine Welfare Award winner
Dr. Todd Duffield named as the 2018 Metacam® 20* Bovine Welfare Award winner
Legal Notices
Legal Notices
Social media community guidelines
Social media community guidelines
World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program
World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program
PIPEDA Terms of Use Consent - Contact us form - english
PIPEDA Terms of Use Consent - Contact us form - english
Accessible Customer Service Policy
Accessible Customer Service Policy
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Life forward - Boehringer Ingelheim unveils its evolved company brand
Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Twenty years of controlling Lawsonia intracellularis
Twenty years of controlling Lawsonia intracellularis
Inadvertent self-injection: The risk associated with oil-based vaccines
Inadvertent self-injection: The risk associated with oil-based vaccines
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Simple and straight to the source: tips for ileitis control
Simple and straight to the source: tips for ileitis control
Choose the better engineered teat sealant
Choose the better engineered teat sealant
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Terms Of Use
TERMS OF USE